brentuximab vedotin + rituximab + etoposide + cyclophosphamide + doxorubicin + dacarbazine + dexamethasone

This is a multi-agent combination chemotherapy regimen composed of seven drugs: - **Brentuximab vedotin** is an antibody-drug conjugate targeting CD30, delivering the cytotoxic agent monomethyl auristatin E to malignant cells. - **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, leading to cell lysis. - **Etoposide** is a topoisomerase II inhibitor that induces DNA strand breaks and apoptosis in rapidly dividing cells. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, inhibiting cell replication. - **Doxorubicin** (also known as hydroxydaunorubicin) intercalates into DNA and inhibits topoisomerase II, causing cytotoxicity. - **Dacarbazine** acts as an alkylating agent after metabolic activation, damaging DNA in cancer cells. - **Dexamethasone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. This combination has been investigated for the treatment of aggressive lymphomas such as relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), particularly in patients who are not eligible for stem cell transplantation or CAR T-cell therapy. The regimen leverages multiple mechanisms—targeted immunotherapy, cytotoxic chemotherapy, and steroid modulation—to maximize antitumor efficacy.